rais fve base solid result
intern biosimilar portfolio progress
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
methodolog valu compani
rais fair valu estim per
share follow solid second-quart result
driver fair valu estim increas near-term
enbrel sale strength due probabl unsustain net
price increas year well promis launch
sever biosimilar europ unit
state saw low-single-digit volum growth
quarter well intern sale growth place
blame overal sale declin mostli lower
price repatha older product face
biosimilar competit biosimilar competit
like intensifi possibl addit neulasta
competitor enter market later year
repatha lower price begin annual later
year encourag strong repatha demand amgen
biosimilar launch earli data firm novel
oncolog pipelin although remain cautiou
extrapol data hand patient multi-billion-
prolia pipelin therapi like help defend
stabl wide moat pressur biosimilar
competit think share
under-valued recent price
biosimilar competit biosimilar repres
new threat opportun firm neulasta
biosimilar competit key headwind sale
stem roughli volum declin
price declin maintain
share long-act market end quarter
unit differenti onpro deliveri
system stabl first quarter expect
addit competit lead steadi double-digit
declin franchis franchis face
new biosimilar epogen
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer supportive-car product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
combin phase trial june keytruda kra
closer declin remov one-tim benefit
declin mostli due lower price
extend contract expect pressur
remain throughout double-digit declin
continu futur year hand
recent first market biosimilar version roch
herceptin avastin biosimilar version
herceptin humira led
million sale europ quarter biosimilar
portfolio also expand expect phase data
biosimilar rituxan third quarter approv
biosimilar remicad decemb
earli oncolog pipelin also progress data
bispecif bcma-target therapi
updat june maintain respons rate
chosen ug dose level patient improv
mrd-neg complet respons rate
commerci potenti drug look limit due
difficult continu infus potenti once-weekli
version data next spring
drug impress data lung
cancer patient see
respons treatment rais fair valu estim
news lung cancer
patient hold mutat model
probabl approv nearli billion probability-
weight sale year forecast expect
updat lung cancer data septemb still
test higher dose also combin drug
antibodi plan start pivot monotherapi
studi immin also announc seen
respons one colorect one appendic cancer
patient chang estim see
extens data addit competit landscap
could becom crowd behind mirati
data end year target
therapi merck/moderna enter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
